Latest Conference Articles

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.

Karyn A. Goodman, MD, MS, provides perspective on the potential advantages of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Patients with papillary high-risk non-muscle-invasive bladder cancer whose disease was BCG-unresponsive showed continued antitumor activity with pembrolizumab monotherapy.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, shares some of her top takeaways from the 2023 ASCO GI Cancers Symposium.

Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.

Real-world data support front-line maintenance with avelumab for patients with locally advanced or metastatic urothelial carcinoma following platinum-based chemotherapy.

The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.

Approximately 30% of patients remained on treatment with darolutamide for over 4 years, according to a long-term safety and tolerability updated from the ARAMIS rollover study.

At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.

Long-term data support a de-escalated dose of tamoxifen for certain women with breast intraepithelial neoplasia who are unable to receive the standard dose.

Patients with RAS-wild-type metastatic colorectal cancer did not experience a benefit in terms of response rate or survival when cetuximab was added to the first cycle of chemotherapy.

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP; and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, discuss practice-changing presentations from the 64th American Society of Hematology Annual Meeting and Exposition.

Patients with hepatocellular carcinoma experienced better health-related quality of life outcomes with tislelizumab vs sorafenib.

Encorafenib plus cetuximab, along with chemotherapy, was linked to antitumor activity and a manageable safety profile in patients with BRAF V600E-mutant metastatic colorectal cancer.

Findings from the phase 3 SUNLIGHT study showed that adding bevacizumab to trifluridine/tipiracil boosted overall survival in metastatic colorectal cancer.

The median overall survival with frontline liposomal irinotecan/NALIRIFOX was 11.1 months vs 9.2 months with nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

The median overall survival with nivolumab plus chemotherapy was 12.8 months, vs 10.7 months with chemotherapy alone, in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

Both the gastric and breast cancer HER2 scoring algorithms may be useful in determining which patients with metastatic colorectal cancer may derive benefit with tucatinib/ trastuzumab.

For patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, treatment with zolbetuximab/mFOLFOX6 yielded a progression-free survival (PFS) of 10.61 months whereas placebo/mFOLFOX6 resulted in a PFS of 8.67 months.

In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.

Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.

Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.

Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.